More than 10 million people around the world suffer from Parkinson's disease, according to the Parkinson's Disease Foundation. Unfortunately, pharmaceutical company Merck (NYSE:MRK) announced last week that it will halt the development of an experimental drug for this indication because of disappointing clinical data. Does Merck have other drugs in development for this disease? Are smaller biotechs making progress in this space? Health-care analyst Max Macaluso discusses these questions in the following video.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.